Nelociguat (BAY60-4552)是一种一氧化氮敏感的可溶性鸟苷酸环化酶激活剂。

Plecanatide is an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, it is approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

ODQ is a selective and irreversible inhibitor of nitric oxide-sensitive guanylyl cyclase.

Cinaciguat is the first of a class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.

Vericiguat targets soluble guanylate cyclase (sGC) and is used for treating heart failure.

Ataciguat is a potent guanylate cyclase activator potentially for the treatment of aortic valve stenosis.

Riociguat是一种口服可用的可溶性鸟苷酸环化酶 (sGC) 刺激剂，用于治疗肺动脉高压。

Lificiguat结合可溶性鸟苷酸环化酶（sGC）的β亚基，在CO存在下Kd为0.6-1.1 μM。

BAY 41-2272 is an activator of guanylate cyclases (sGC).

BAY 41-8543 reverses PAH and vascular structural remodeling in MCT-treated rats as a pulmonary hypertension treatment molecule.